Advanced Search

 

Study ID Status Title Patient Level Data
ADF104070 Completed An open label study of adefovir dipivoxil for the treatment of patients with chronic hepatitis B related advanced fibrosis or cirrhosis.
ADF105220 Completed Phase III study of Adefovir Dipivoxil tablets in patients with compensated chronic hepatitis B -Comparative study against Lamivudine-
ADF106632 Completed A 2-year multi-centre, open-label, local phase IV study to demonstrate the efficacy and safety of adefovir dipivoxil tablets (10mg) in Chinese subjects with HBe antigen negative Chronic Hepatitis B
ADF108005 Completed A phase IV, open label, single arm, multicenter, extension study of adefovir dipivoxil for Korean patients with chronic hepatitis B(CHB) who have completed ADF 103814
ADF108356 Completed A 48-week multi-centre, open-label, local phase IV study to demonstrate the efficacy and safety of adefovir dipivoxil tablets (10mg) in Chinese subjects with compensated Chronic Hepatitis B
ADF30001 Completed A Multi-Centre, Double-Blind , Randomized, Placebo-Controlled Phase II/III Study of Adefovir Dipivoxil for the Treatment of Chinese Patients with HBeAg positive Chronic Hepatitis B Followed by Long-term (5 Years total) Adefovir Dipivoxil Treatment. (Report on Year 1 and Year 2 Data)
ADG103440 Completed A randomised,double-blind, parallel group, placebo-controlled, multicentre study to evaluate the safety, tolerability and efficacy of oral GW677954 capsules 2.5mg, 5mg, 10mg and 20mg a day for 24 weeks in overweight dyslipidaemic subjects Study Listed on ClinicalStudyDataRequest.com
ADG104148 Completed An exploratory MRI study in Type 2 diabetic subjects: A randomized, double-blinded, placebo-controlled trial to evaluate the measurement of fluid volumes by MRI in the lower extremities of subjects receiving pioglitazone
ADG106149 Terminated A Randomized, Double-blind, Parallel, Placebo-Controlled, Study to Evaluate the Safety and Tolerability of Oral GW677954 Capsules (15 mg) in Combination With Insulin in Subjects with Type 2 Diabetes Mellitus
ADG20001 Completed A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients with Type 2 Diabetes Mellitus Study Listed on ClinicalStudyDataRequest.com
AK1102364 Completed An Open-Label, Multi-Cetre, Phase II Study Evaluating the Safety and Efficacy of 323U66 SR in Patients with Depression
AK1102365 Completed Clinical evaluation of 323U66 SR in patients with depression - Placebo-controlled, double-blind, comparative study in patients with depression who did not respond sufficiently to selective serotonin re-uptake inhibitors
AK1102369 Completed Clinical Evaluation of 323U66 SR in patients with Depression – Investigation in Elderly patients with Depression –
AK130926 Completed A Multicenter, Double-Blind, Randomized, Placebo Controlled Comparison of the Effects on Sexual Functioning of Extended-Release Bupropion Hydrochloride (300-450mg) and escitalopram (10-20mg) in Outpatients with Moderate to Severe Major Depression over an Eight-Week Treatment Period
AK130927 Completed A Multicenter, Double-blind Randomized Placebo-controlled Comparison of the Effects on Sexual Functioning of Extended-release Bupropion Hydrochloride (300-450mg) and Escitalopram (10-20mg) in Outpatients with Moderate to Severe Major Depression over an Eight-Week Treatment Period
AK130930 Completed A 7-Month, Multicenter, Randomized, Double-Blind, Placebo-Controlled Comparison of 150-300mg/day of Extended-Release Bupropion Hydrochloride (WELLBUTRIN XL) and Placebo for the Prevention of Seasonal Affective Disorder in Subjects with a History of Seasonal Affective Disorder Followed by an 8-Week Observational Follow-up Phase
AK130931 Completed An 8 week, multicenter, randomized, double-blind, placebo controlled comparison of the efficacy of extended release bupropion hydrochloride and placebo in the treatment of adult outpatients with major depressive disorder with lethargic symptoms
AK130934 Completed An 8-week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Comparison of Extended-Release Bupropion Hydrochloride 300-450 mg/day to Assess the Efficacy, Safety, and Effects on Health Outcomes in the Treatment of Adults with Attention-Deficit/Hyperactivity Disorder
AK130936 Completed A 7 Month, Multicenter, Randomized, Double-blind, Placebo-Controlled Comparison of 150-300 mg/day of Extended-release Bupropion Hydrochloride and Placebo for the Prevention of Seasonal Affective Disorder in subjects with a History of Seasonal Affective Disorder Followed by an 8-week Observational Follow-up Phase
AK130940 Completed A Multi-Centre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible Dose Study to Evaluate the Efficacy, Safety and Tolerability of Extended-release Bupropion Hydrochloride (150mg-300mg once daily) in Elderly Subjects with Major Depressive Disorder
AKT106757 Terminated An Open-label Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the AKT Inhibitor GSK690693 given on Various Schedules in Subjects with Solid Tumors or Lymphoma Study Listed on ClinicalStudyDataRequest.com
AKT108169 Withdrawn A Phase I Open-label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Potential Anti-cancer Activity of the AKT Inhibitor GSK690693 in Subjects with Relapsed or Refractory Hematologic Malignancies
ALB110247 Completed Randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK) and efficacy of Retapamulin ointment, 1% applied twice daily for 3 or 5 days to the anterior nares of healthy adult subjects nasally colonized with Staphylococcus aureus Study Listed on ClinicalStudyDataRequest.com
AMB107623 Completed Phase I study of ambrisentan – Single dose study in healthy Japanese male subjects
AMB107816 Completed Study AMB107816, Clinical Evaluation of GSK1325760A in the Treatment of Pulmonary Arterial Hypertension (PAH)- An Open-Label Phase II/III Study to evaluate the Efficacy, Safety and Pharmacokinetics of GSK1325760A -<Classification: Exploratory and confirmatory clinical trial>

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.